Wedbush Starts Audentes Therapeutics (BOLD) at Outperform

Wedbush initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating and a price target of $20.

"BOLD’s AAV-based gene therapy programs are targeted to address significant unmet medical need in life-threatening rare diseases. With clinical readouts expected in 2017 from three wholly-owned programs backed by robust preclinical data, we view BOLD shares as a compelling opportunity," said analyst David M. Nierengarten.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $14.70 yesterday.

You May Also Be Interested In

• B.Riley Starts Whitehawk Therapeutics (WHWK) at Buy
• Lake Street Downgrades Identiv, Inc. (INVE) to Hold
• Monness, Crespi, Hardt Upgrades Workday (WDAY) to Buy